Publication
Infringement risk relating to creation and use of the output of a generative AI system
Where the Output of a generative AI system is the same or substantially similar to a third party’s copyright work
Pharmaceutical Intellectual Property and Competition Law Review
Publication | November 2020
COVID-19 has put a significant focus on the pharmaceutical industry in the development of treatments and a vaccine. Because the pharmaceutical business is a global industry, legal frameworks vary from region to region, especially in the area of intellectual property. The Pharmaceutical Intellectual Property and Competition Law Review examines the complexities of the industry in multiple jurisdictions providing a useful tool for managing global risks.
Norton Rose Fulbright Canada contributed to this publication, providing an overview of the intellectual property laws in Canada and how they interact with Canada’s competition law.
Recent publications
Publication
Is the output of the generative AI system protected by intellectual property rights?
The approach and requirements for intellectual property rights to subsist in computer-generated works vary from jurisdiction to jurisdiction.
Publication
Infringement risk relating to training a generative AI system
Generative AI systems are trained using vast amounts of data, often taken from sources in the public domain that may be protected by copyright or other intellectual property rights, such as, in the UK and EU, a database right.
Subscribe and stay up to date with the latest legal news, information and events . . .